| dc.contributor | Vall d'Hebron Barcelona Hospital Campus |
| dc.contributor.author | Rando Segura, Ariadna |
| dc.contributor.author | Ubeda, Maria |
| dc.contributor.author | Valls, Imma |
| dc.contributor.author | Ventosa, Carla |
| dc.contributor.author | García Hernandez, Nuria |
| dc.contributor.author | Romero Vico, judit |
| dc.contributor.author | Vargas-Accarino, Elena |
| dc.contributor.author | Palom, Adriana |
| dc.contributor.author | Ruiz Cobo, Juan Carlos |
| dc.contributor.author | Buti Ferret, Maria |
| dc.date.accessioned | 2025-11-25T12:10:11Z |
| dc.date.available | 2025-11-25T12:10:11Z |
| dc.date.issued | 2025-10 |
| dc.identifier.citation | Vargas-Accarino E, Rando-Segura A, Úbeda MA, Valls I, Ventosa C, García N, et al. Beyond Risk Factors: Rethinking Hepatitis B and Hepatitis C Screening in Primary Care. Liver Int. 2025 Oct;45(10):e70330. |
| dc.identifier.issn | 1478-3231 |
| dc.identifier.uri | http://hdl.handle.net/11351/14102 |
| dc.description | hepatitis B; hepatitis C; Primary care |
| dc.description.abstract | Introduction
Most international guidelines recommend screening for hepatitis B virus (HBV) and hepatitis C virus (HCV) only for individuals with risk factors or elevated ALT levels. However, this approach may not suffice to eradicate viral hepatitis. This study evaluates the application of EASL HBV and HCV screening guidelines in primary care centres (PCCs).
Methods
The study included two components: (1) A retrospective review (January 2021–March 2023) of microbiology data to determine testing rates, analyse clinical characteristics, and assess management; and (2) A prospective intervention (March–April 2024) involving HBV and HCV screening and risk factor surveys for all adults attending two PCCs for blood collection.
Results
In the retrospective analysis of 90 170 patients, HBV and HCV screening rates were 16% and 10%, respectively. Among HBsAg-positive patients (n = 84 (0.5%)), 67% lacked risk factors or elevated ALT. Among anti-HCV-positive (n = 277 (3%)) and HCV RNA-positive (n = 45 (0.5%)) patients, 54% and 46% respectively lacked these indicators.
In the prospective study of 1030 patients (mean age 55, 39.6% men, 73% Spanish), anti-HCV was detected in 1.16% of cases (HCV RNA in 0.19%). Of these, 67% lacked risk factors or elevated ALT. No HBsAg-positive cases were identified, and hepatitis B vaccination status was uncertain for 50% of patients.
Conclusion
Risk factor-based screening for HBV and HCV in primary care is a suboptimal approach. More than half of the patients testing positive lacked identifiable risk factors or elevated ALT levels. Universal one-time screening for all adults could address these limitations and significantly advance viral hepatitis elimination efforts. |
| dc.language.iso | eng |
| dc.publisher | Wiley |
| dc.relation.ispartofseries | Liver International;45(10) |
| dc.rights | Attribution 4.0 International |
| dc.rights.uri | http://creativecommons.org/licenses/by/4.0/ |
| dc.source | Scientia |
| dc.subject | Hepatitis B - Diagnòstic |
| dc.subject | Hepatitis C - Diagnòstic |
| dc.subject | Hepatitis C - Factors de risc |
| dc.subject | Hepatitis B - Factors de risc |
| dc.subject | Cribatge (Medicina) |
| dc.subject.mesh | Risk Factors |
| dc.subject.mesh | Hepatitis B |
| dc.subject.mesh | Hepatitis C |
| dc.subject.mesh | Mass Screening |
| dc.title | Beyond Risk Factors: Rethinking Hepatitis B and Hepatitis C Screening in Primary Care |
| dc.type | info:eu-repo/semantics/article |
| dc.identifier.doi | 10.1111/liv.70330 |
| dc.subject.decs | factores de riesgo |
| dc.subject.decs | hepatitis B |
| dc.subject.decs | hepatitis C |
| dc.subject.decs | cribado sistemático |
| dc.relation.publishversion | https://doi.org/10.1111/liv.70330 |
| dc.type.version | info:eu-repo/semantics/publishedVersion |
| dc.audience | Professionals |
| dc.contributor.organismes | Institut Català de la Salut |
| dc.contributor.authoraffiliation | [Vargas-Accarino E] Departament de Medicina, Universitat Autònoma de Barcelona, Bellaterra, Spain. Grup de Recerca de les Malalties Hepàtiques, Vall d’Hebron Institut de Recerca (VHIR), Barcelona, Spain. CIBERehd, enfermedades hepáticas y digestivas, Madrid, Spain. [Rando-Segura A] CIBERehd, enfermedades hepáticas y digestivas, Madrid, Spain. Servei de Microbiologia, Vall d’Hebron Hospital Universitari, Barcelona, Spain. [Úbeda MA] CAP Horta, Barcelona, Spain. [Valls I] CAP San Rafael, Barcelona, Spain. [Ventosa C] CAP Guineueta, Barcelona, Spain. [García N] CAP Río de Janeiro, Barcelona, Spain. [Palom A] Grup de Recerca de les Malalties Hepàtiques, Vall d’Hebron Institut de Recerca (VHIR), Barcelona, Spain. CIBERehd, enfermedades hepáticas y digestivas, Madrid, Spain. [Romero-Vico J] Grup de Recerca de les Malalties Hepàtiques, Vall d’Hebron Institut de Recerca (VHIR), Barcelona, Spain. [Ruiz-Cobo JC, Buti M] Departament de Medicina, Universitat Autònoma de Barcelona, Bellaterra, Spain. Grup de Recerca de les Malalties Hepàtiques, Vall d’Hebron Institut de Recerca (VHIR), Barcelona, Spain. CIBERehd, enfermedades hepáticas y digestivas, Madrid, Spain. Servei d’Hepatologia, Vall d’Hebron Hospital Universitari, Barcelona, Spain |
| dc.identifier.pmid | 40970664 |
| dc.identifier.wos | 001574521600001 |
| dc.relation.projectid | info:eu-repo/grantAgreement/ES/PEICTI2021-2023/PI23%2F01065 |
| dc.rights.accessrights | info:eu-repo/semantics/openAccess |